Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Top Five Takeaways From World's Largest Dermatology Conference

Executive Summary

As the American Academy of Dermatology meeting ends in Boston, Scrip looks at some of the key data presented at the congress covering the latest advances in the hot area of atopic dermatitis, alopecia and butterfly skin.

You may also be interested in...



Concert’s CTP-543 Shows Advantages Over Lilly, Pfizer Candidates For Alopecia

Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.

Almirall Views Vitiligo As Next Dermatology Opportunity

As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.

Amryt Earns Wings For Butterfly Skin Drug In Europe

CEO Joe Wiley has said the backing of the EMA's advisory committee for its epidermolysis bullosa gel represents "the most significant milestone in Amryt’s history" and is a massive boost for the Dublin-headquartered group after getting a complete response letter in the US a couple of months ago.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel